- My Alerts
- Go Ad-Free
-
My Account
In App
| BUY | SELL | ||
|---|---|---|---|
| QTY | PRICE | PRICE | QTY |
| 6 | 762.20 | 763.00 | 106 |
| 22 | 762.15 | 763.50 | 4 |
| 33 | 762.00 | 763.90 | 26 |
| 2 | 761.95 | 763.95 | 24 |
| 26 | 761.90 | 764.50 | 47 |
| 13980 | Total | Total | 6440 |
| BUY | SELL | ||
|---|---|---|---|
| QTY | PRICE | PRICE | QTY |
| 6 | 762.20 | 763.00 | 106 |
| 22 | 762.15 | 763.50 | 4 |
| 33 | 762.00 | 763.90 | 26 |
| 2 | 761.95 | 763.95 | 24 |
| 26 | 761.90 | 764.50 | 47 |
| 13980 | Total | Total | 6440 |
| Open | 757.50 |
| Previous Close | 757.50 |
| Volume | 33,773.00 |
| Value (Lacs) | 257.55 |
| VWAP | 756.43 |
| Beta | |
| Mkt Cap (Rs. Cr.) | 14,990 |
| High | 767.80 |
| Low | 750.20 |
| UC Limit | 909.00 |
| LC Limit | 606.00 |
| 52 Week High | 1,107.90 |
| 52 Week Low | 635.80 |
| Face Value | 2.00 |
| All Time High | 1,303.90 |
| All Time Low | 31.00 |
| 20D Avg Volume | 130,793 |
| 20D Avg Delivery(%) | 54.69 |
| Book Value Per Share | 277.42 |
| Dividend Yield | 1.44 |
| TTM EPS See historical trend | 32.00 (+4.01% YoY) |
| TTM PE See historical trend | 23.83 (Low PE) |
| P/B See historical trend | 2.75 (Low P/B) |
| Sector PE | 39.83 |
*Delayed by 20 seconds.
Stock Score
Get detailed analysis with Moneycontrol Stock Insights.
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
| Days | |
|---|---|
| 5 | - - |
| 10 | - - |
| 20 | - - |
| 50 | - - |
| 100 | - - |
| 200 | - - |
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
| Days |
|---|
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
| Days |
|---|
| 1 Week | --% | |
| 1 Month | --% | |
| 3 Months | --% | |
| YTD | --% | |
| 1 Year | --% | |
| 3 Years | --% |
12 out of 15 years Alembic Pharmaceuticals has given positive returns in April.
| Month | Max. Positive Change(%) | Avg. Positive Change(%) | Max. Negative Change(%) | Avg. Negative Change(%) | Average Change(%) |
|---|---|---|---|---|---|
| April | 39.17% (2020) | 9.13% | -5.83% (2025) | -3.62% | 6.58% |
Alembic Pharma Consolidated December 2025 Net Sales at Rs 1,876.31 crore, up 10.84% Y-o-Y Feb 18 2026 01:41 PM
Alembic Pharma Standalone December 2025 Net Sales at Rs 1,642.24 crore, up 16.79% Y-o-Y Feb 09 2026 11:26 AM
Neutral Alembic Pharma; target of Rs 860: Motilal Oswal Feb 06 2026 05:52 PM
Alembic Pharma pivots to US branded market, set to launch women's 'health antibiotic' Feb 06 2026 01:10 PM
Alembic Pharma gets USFDA final approval for Methotrexate Injection Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration USFDA for its Abbreviated New Drug Application ANDA Methotrexate Injection USP, 50 mg,2 mL 25 mg,mL Multi-Dose Vials and 1g,40 mL 25 mg,mL SingleDose Vials. View more
Posted by : kamal20
Repost this message
Alembic Pharma gets USFDA final approval for Methotrexate Injection Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration USFDA for its Abbreviated New Drug Application ANDA Methotrexate Injection USP, 50 mg,2 mL 25 mg,mL Multi-Dose Vials and 1g,40 mL 25 mg,mL SingleDose Vials.
Posted by : The Fixed Income
Repost this message
Floating-rate bonds are linked to a benchmark rate, such as a government or market rate, which determines how the interest is reset, while fixed-rate bonds are not linked to any benchmark. https://www.thefixedincome.com/products?utm_source=moneycontrol&utm_medium=mc-forum&utm_campaign=explore-all-products
*Transaction of a minimum quantity of 500,000 shares or a minimum value of Rs 5 crore.
*A bulk deal is a trade where total quantity of shares bought or sold is more than 0.5% of the equity shares of a company listed on the exchange.
| Qty 10,000 | Price 903.55 | % Traded 0.01 |
| Qty 15,000 | Price 925.37 | % Traded 0.01 |
| Qty 5,000 | Price 901.78 | % Traded 0.00 |
| Qty 5,200 | Price 962.23 | % Traded 0.00 |
| Qty 25,000 | Price 959.34 | % Traded 0.01 |
| Qty 20,000 | Price 948.05 | % Traded 0.01 |
| Qty 13,068 | Price 963.49 | % Traded 0.01 |
| Qty 20,000 | Price 955.98 | % Traded 0.01 |
| Date | Agenda |
|---|
| Ex-Date | Type | Dividend (Rs) |
|---|
| Announcement Date | Ex-Bonus | Ratio |
|---|
| Ex-Split | Old FV | New FV |
|---|
| Ex-Right | Ratio | Premium |
|---|
| Date | Agenda |
|---|
Sharpest Opinions & Actionable Insights 
Exclusive Webinars 
Research & Expert Technical Analysis 
